163 related articles for article (PubMed ID: 37694398)
1. A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom.
Campling J; Vyse A; Liu HH; Wright H; Slack M; Reinert RR; Drayson M; Richter A; Singh D; Barlow G; Kassianos G; Ellsbury G
Expert Rev Vaccines; 2023; 22(1):785-800. PubMed ID: 37694398
[TBL] [Abstract][Full Text] [Related]
2. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK.
Vyse A; Campling J; Czudek C; Ellsbury G; Mendes D; Reinert RR; Slack M
Expert Rev Vaccines; 2021 Oct; 20(10):1311-1325. PubMed ID: 34550850
[TBL] [Abstract][Full Text] [Related]
3. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
4. Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature.
Arya S; Norton N; Kaushik P; Brandtmüller A; Tsoumani E
Hum Vaccin Immunother; 2023 Dec; 19(3):2279394. PubMed ID: 38014651
[TBL] [Abstract][Full Text] [Related]
5. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
[TBL] [Abstract][Full Text] [Related]
6. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
8. The impact of the changing pneumococcal national immunisation program among older Australians.
Menzies R; Stein AN; Booy R; Van Buynder PG; Litt J; Cripps AW
Vaccine; 2021 Jan; 39(4):720-728. PubMed ID: 33384189
[TBL] [Abstract][Full Text] [Related]
9. Ten years of experience with the pneumococcal non-typeable
Lecrenier N; Marijam A; Olbrecht J; Soumahoro L; Nieto Guevara J; Mungall B
Expert Rev Vaccines; 2020 Mar; 19(3):247-265. PubMed ID: 32195602
[No Abstract] [Full Text] [Related]
10. Advances in pneumococcal vaccines: what are the advantages for the elderly?
Vila-Córcoles A
Drugs Aging; 2007; 24(10):791-800. PubMed ID: 17896829
[TBL] [Abstract][Full Text] [Related]
11. The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development.
Vyse A; Campling J; Czudek C; Ellsbury G; Slack M
Vaccine; 2020 Dec; 38(51):8068-8070. PubMed ID: 33190949
[No Abstract] [Full Text] [Related]
12. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease.
Kopp A; Mangin O; Gantzer L; Lekens B; Simoneau G; Ravelomanantsoa M; Evans J; Bergmann JF; Sellier P
Hum Vaccin Immunother; 2021 Jan; 17(1):162-169. PubMed ID: 32429734
[No Abstract] [Full Text] [Related]
13. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
14. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
Lexau CA; Lynfield R; Danila R; Pilishvili T; Facklam R; Farley MM; Harrison LH; Schaffner W; Reingold A; Bennett NM; Hadler J; Cieslak PR; Whitney CG;
JAMA; 2005 Oct; 294(16):2043-51. PubMed ID: 16249418
[TBL] [Abstract][Full Text] [Related]
15. Invasive Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia: implications for India.
Kolhapure S; Yewale V; Agrawal A; Krishnappa P; Soumahoro L
J Infect Dev Ctries; 2021 Jun; 15(6):749-760. PubMed ID: 34242182
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
[TBL] [Abstract][Full Text] [Related]
17. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal vaccination of elderly adults: new paradigms for protection.
Jackson LA; Janoff EN
Clin Infect Dis; 2008 Nov; 47(10):1328-38. PubMed ID: 18844484
[TBL] [Abstract][Full Text] [Related]
20. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
